MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

36.47
-0.62
-1.67%
After Hours: 36.30 -0.17 -0.47% 16:19 09/23 EDT
OPEN
36.88
PREV CLOSE
37.09
HIGH
38.38
LOW
36.20
VOLUME
986.22K
TURNOVER
--
52 WEEK HIGH
39.45
52 WEEK LOW
12.59
MARKET CAP
3.17B
P/E (TTM)
-23.2708
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Hedge Funds Are Absolutely Crazy About Fate Therapeutics Inc (FATE)
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index
Insider Monkey · 09/11 15:11
Fate Therapeutics Announces September Investor Events
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming investor conferences
GlobeNewswire · 09/04 12:00
Fate Therapeutics gets new CFO
Fate Therapeutics ([[FATE]] +0.4%) announced that Edward Dulac has been appointed CFO.Mr. Dulac comes to the Company from Celgene, where he most recently served as VP, Business Development & Strategy, and
Seekingalpha · 08/19 14:16
Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer
SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointed Chief Financial Officer
GlobeNewswire · 08/19 13:00
Shares Of Fate Therapeutics Move Higher; Traders Circulate The Stem Cellar Post Highlighting Success Of Co.'s FT516 In Coronavirus Trial
https://blog.cirm.ca.gov/2020/08/12/therapy-developed-with-cirm-award-used-in-new-clinical-trial-for-covid-19/
Benzinga · 08/12 17:47
Fate Therapeutics (FATE) Reports Q2 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -75.00% and -73.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 21:55
Fate Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Operational Progress
Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for A
GlobeNewswire · 08/05 20:01
Fate Therapeutics Q2 2020 Earnings Preview
Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q2 earnings results on Wednesday, August 5th, after market close. The consensus EPS Estimate is -$
seekingalpha · 08/05 02:35
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FATE. Analyze the recent business situations of Fate through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FATE stock price target is 39.50 with a high estimate of 59.00 and a low estimate of 29.00.
EPS
Institutional Holdings
Institutions: 251
Institutional Holdings: 90.44M
% Owned: 104.14%
Shares Outstanding: 86.84M
TypeInstitutionsShares
Increased
71
11.80M
New
68
4.85M
Decreased
51
6.43M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.78%
Pharmaceuticals & Medical Research
-1.14%
Key Executives
Chairman/Independent Director
William Rastetter
President/Chief Executive Officer/Director
J. Scott Wolchko
President/Chief Executive Officer/Director
John Wolchko
Vice Chairman/Independent Director
John Mendlein
Chief Financial Officer
Edward Dulac
Senior Vice President
Sarah Cooley
Chief Scientific Officer
Daniel Shoemaker
Vice President
Yu-Waye Chu
General Counsel/Secretary
Cindy Tahl
Other
Bahram Valamehr
Director
Shefali Agarwal
Director
Robert Hershberg
Independent Director
Timothy Coughlin
Independent Director
Robert Epstein
Independent Director
Karin Jooss
Independent Director
Michael Lee
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FATE
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.